About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« 12 Senators Write in Support of 12-Year Data Exclusivity Period | Main | Biotech/Pharma Docket »

November 03, 2009


Well, I guess there is no question about the fix being in since this is now in the Obamacare bill. One more potentially adverse constituency bought off by the Democrats. This bill is turning into a cesspool of corruption.


Given that the health care bill is likely to go nowhere this year (unless there's a huge surprise), having a biosimilar pathway in this bill may be academic for the moment. But it's nice to see a "bipartisan" recognition that granting too short a period of "data exclusivity" could make development of biologic drugs commercially unattractive. Put it this way, as Kevin has correctly said, there is no biosimilar pathway now, so any pathway in this bill is better for FOBs compared with what currently exists.

The comments to this entry are closed.

May 2024

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31